---
title: "N-Acetyl Semax Amidate"
canonical_url: https://peptidelibrary.app/library/n-acetyl-semax-amidate
description: "N-acetylated, C-amidated Semax analog sold for nootropic research, intended to resist peptidases versus standard Semax. Not FDA-approved."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# N-Acetyl Semax Amidate

N-Acetyl Semax Amidate (also called NASA) is a modified Semax analog. This is Semax carrying two standard medicinal-chemistry modifications: acetylation of the N-terminus and amidation of the C-terminus. Both changes block exopeptidase attack at the chain ends, the usual route of degradation for short peptides, and the added lipophilicity is the stated rationale for intranasal use.

N-acetylated, C-amidated Semax analog sold for nootropic research, intended to resist peptidases versus standard Semax. Not FDA-approved.

Also known as: NASA.

Categories: Cognitive, Experimental.

## Classification

- Type: Modified Semax analog / research
- Mechanism class: ACTH Analog
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

This is Semax carrying two standard medicinal-chemistry modifications: acetylation of the N-terminus and amidation of the C-terminus. Both changes block exopeptidase attack at the chain ends, the usual route of degradation for short peptides, and the added lipophilicity is the stated rationale for intranasal use. The underlying pharmacology is assumed to match Semax — modulation of brain-derived neurotrophic factor expression and of monoamine transmission, without the corticotropic activity of the ACTH parent. Comparative pharmacokinetic data between the modified and unmodified forms has not been published, so claims of greater potency or duration should be treated as unverified.

Targets: Melanocortin-related CNS pathways, BDNF (by analogy to Semax).

Origin: Synthetic modified Semax.

## Properties

- Molecular formula: C39H54N10O10S
- Molecular weight: 855 g/mol
- CAS number: 2920938-90-3

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: None documented
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova. 1997. 1997. Human study (early or uncontrolled). Population: Adults in the acute period of ischaemic stroke (n=30, with 80 conventionally treated controls). Faster recovery of neurological, especially motor, function reported. Research on a related compound, not this one. Limitations: Studied an analog, not N-Acetyl Semax Amidate itself [Source](https://pubmed.ncbi.nlm.nih.gov/11517472/)
2. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. 2018. Human study (early or uncontrolled). Population: Adults after ischaemic stroke (n=110, semax and non-semax subgroups). Higher plasma BDNF levels and better motor and Barthel scores reported. Research on a related compound, not this one. Limitations: Studied an analog, not N-Acetyl Semax Amidate itself [Source](https://pubmed.ncbi.nlm.nih.gov/29798983/)

## Safety

Side effects: Nasal irritation if used IN; Unknown chronic safety.

Risks: Research-only.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

N-Acetyl Semax Amidate is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is N-Acetyl Semax Amidate?

N-acetylated, C-amidated Semax analog sold for nootropic research, intended to resist peptidases versus standard Semax. Not FDA-approved.

### How does N-Acetyl Semax Amidate work?

This is Semax carrying two standard medicinal-chemistry modifications: acetylation of the N-terminus and amidation of the C-terminus. Both changes block exopeptidase attack at the chain ends, the usual route of degradation for short peptides, and the added lipophilicity is the stated rationale for intranasal use.

### Is N-Acetyl Semax Amidate FDA approved?

No. N-Acetyl Semax Amidate is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What peptides are similar to N-Acetyl Semax Amidate?

Compounds most often compared with N-Acetyl Semax Amidate include Semax, Adamax, Selank and Cerebrolysin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Class-level evidence — Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus — Brain Res, 2006](https://pubmed.ncbi.nlm.nih.gov/16996037/)
- [Class-level evidence — Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026](https://pubmed.ncbi.nlm.nih.gov/41490200/)
- [Class-level evidence — Functional Connectomic Approach to Studying Selank and Semax Effects — Dokl Biol Sci, 2020](https://pubmed.ncbi.nlm.nih.gov/32342318/)
- [Class-level evidence — ACTH(4-10) protects the ADR-injured podocytes by stimulating B lymphocytes to secrete interleukin-10 — Int Immunopharmacol, 2020](https://pubmed.ncbi.nlm.nih.gov/32682256/)
- [Class-level evidence — Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats — Neuropeptides, 2021](https://pubmed.ncbi.nlm.nih.gov/33418449/)
